miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM)

Zongze He1,2†, Meixiong Cheng1†, Junting Hu1†, Lingtong Liu1, Ping Liu1, Longyi Chen1*, Deqian Cao1* and Jian Tang1*

Abstract
Background: Gliomas account for about 80% of all malignant brain and other central nervous system (CNS) tumors. Temozolomide (TMZ) resistance represents a major treatment hurdle. Adrenomedullin (ADM) has been reported to induce glioblastoma cell growth.

Methods: Cell viability was measured using the CCK-8 assay. The apoptosis analysis was performed using the Annexin V-FITC Apoptosis Detection Kit. The mitochondrial membrane potential was determined by JC-1 staining. A nude mouse tumor assay was used to detect tumor formation. Hematoxylin and eosin (H&E) and immunohistochemical (IHC) staining were performed in tissue sections. Activation of Akt and Erk and expression of apoptosis-related proteins were determined by immunoblotting.

Results: ADM expression has been found upregulated in TMZ-resistant glioma samples based on bioinformatics and experimental analyses. Knocking down ADM in glioma cells enhanced the suppressive effects of TMZ on glioma cell viability, promotive effects on cell apoptosis, and inhibitory effects on mitochondrial membrane potential. Moreover, ADM knockdown also enhanced TMZ effects on Bax/Bcl-2, Akt phosphorylation, and Erk1/2 phosphorylation. Bioinformatics and experimental investigation indicated that miR-1297 directly targeted ADM and inhibited ADM expression. miR-1297 overexpression exerted similar effects to ADM knockdown on TMZ-treated glioma cells. More importantly, under TMZ treatment, inhibition of miR-1297 attenuated TMZ treatment on glioma cells; ADM knockdown partially attenuated the effects of miR-1297 inhibition on TMZ-treated glioma cells.

Conclusions: miR-1297 sensitizes glioma cells to TMZ treatment through targeting ADM. The Bax/Bcl-2, Akt, and Erk1/2 signaling pathways, as well as mitochondrial functions might be involved.

Keywords: Gliomas, Temozolomide (TMZ), Sensitivity, Adrenomedullin (ADM), miR-1297
radiotherapy and chemotherapy, especially temozolomide (TMZ), which is the most commonly used clinical chemotherapy for Glioblastoma [3, 4]. TMZ can efficiently cross the blood–brain barrier and induce glioma cell apoptosis; however, chemotherapy resistance often develops and represents a major treatment hurdle. Since glioma resistance to TMZ is associated with multiple factors, identifying more factors that enhance glioma cell sensitivity to TMZ may be an effective intervention to improve the prognosis of patients.

Adrenomedullin (ADM), an effective vasodilator peptide composed of 52 amino acids, is first found in human pheochromocytoma. ADM shows expression in human lung, breast, brain, prostate, colon, and other tumor cell lines [5]. ADM mRNA expression in brain tumors is correlated with the type and grade of tumors [6]. In an oncology environment, ADM influences tumor cell growth, angiogenesis and apoptosis [16, 18–21]. Interestingly, several miRNAs, including miR-27a-3p [22], miR-93 [23], miR-26a [24], miR-1238 [25], miR-129-5p [26], miR-519a [27] and so on, have been reported involved in glioma resistance to TMZ treatment. Thus, searching for miRNAs that might target ADM might be a promising strategy for improving glioma resistance to TMZ.

Herein, we verified ADM expression in TMZ-resistant and -sensitive glioma samples using bioinformatics and experimental analyses. ADM knockdown was achieved in glioma cells and the specific effects of ADM knockdown on glioma sensitivity to TMZ were investigated. We employed five online tools to predict miRNAs targeting ADM; miR-1297 was selected after confirming the expression profiles of predicted candidates. The predicted miR-1297 binding to ADM and miR-1297 regulation of ADM were verified. The specific effects of miR-1297 overexpression on glioma sensitivity to TMZ were investigated. Lastly, the dynamic effects of the miR-1297/ADM axis on glioma sensitivity to TMZ were investigated.

Materials and methods
Clinical samples collection
A total of 18 glioma tissue samples and 18 noncancerous adjacent tissue samples (peritumoral brain edema tissue) were obtained from patients undergoing surgical treatment at Sichuan Provincial People’s Hospital under the approval of the Ethics Committee of Sichuan Provincial People’s Hospital. All enrolled patients provided written informed consent. All the tissues were kept at −80 °C or fixed in 4% paraformaldehyde before further experiments.

Bioinformatic analysis
Expression data from Gene Expression Omnibus (GEO) datasets, The Cancer Genome Atlas Glioma (TCGA-GBMLGG) were downloaded. GSE68029 contains the expression profiling of 6 untreated glioblastoma stem cells (GSC) and 6 resistant GSC clones (survived from 500 μM TMZ treatment). GSE113510 contains the expression profiling of 3 LN-229 cells and 3 TMZ-resistant LN-229 cells. GSE46531 contains the expression profiling of 6 radiation-treated GSCs and 6 radiation-treated TMZ-resistant GSCs. The expression of ADM in different groups was analyzed by Student’s t-test (P-value < 0.05). For overall survival analysis of ADM, the expression matrix of TCGA-GBMLGG (n = 625) and Chinese Glioma Genome Atlas (CGGA) (n = 601) and correlated survival data were analyzed by R language packages survival and survminer.

Cell treatment
Human non-cancerous glial cell line SVG p12 (CRL-8621) and human glioma cell lines [U87-MG (HTB-14)]
and T98G (CRL-1690) were cultured (37 °C, 5% CO₂) in Eagle’s Minimum Essential Medium (EMEM; 30–2003) containing 10% FBS (Gibco, Waltham, MA, USA). Human glioma cell lines [A-172 (CRL-1620) and LN-229 (CRL-2611)] were kept (37 °C, 5% CO₂ in 10% FBS (Gibco)-supplemented Dulbecco’s Modified Eagle’s Medium (DMEM; 30–2002). All cells and medium were obtained from ATCC (Manassas, VA, USA). For TMZ

![Fig. 1](image1.png) ADM is specifically up-regulated in TMZ-resistant glioblastoma cell strains. A The expression of ADM in untreated glioblastoma stem cells (GSCs) and GSCs that survived after 500μM temozolomide (TMZ) treatment, according to GSE68029. B The expression of ADM in induced TMZ-resistant LN229 cells and regular LN229 cells, according to GSE113510. C The expression of ADM in TMZ treatment sensitive glioblastoma stem cell clones and TMZ treatment resistant glioblastoma stem cell clones according to GSE46531. D The expression of ADM in samples with or without radiation-therapy, according to TCGA-GBMLGG. E ADM expression was determined in a normal human glial cell line SVG p12 and four glioma cell lines, U87-MG, A-172, LN-229, and T98G using qRT-PCR.

![Fig. 2](image2.png) ADM knockdown sensitizes glioma cells to TMZ treatment. A ADM knockdown was achieved in LN-229 cells by transfecting short hairpin RNA targeting ADM (sh1-ADM or sh2-ADM). ADM knockdown was confirmed using qRT-PCR. Then, LN-229 cells were transfected with sh-NC or sh-ADM, treated or non-treated with TMZ, and examined for cell viability by CCK-8 assay (B); cell apoptosis by Flow cytometry (C); the protein levels of ADM, cleaved caspase 3, pro-caspase 3, cleaved caspase 9, pro-caspase 9, Bax, Bcl-2, p-Akt, Akt, p-Erk1/2, Erk1/2 and cleaved PARP by Immunoblotting (D); mitochondrial membrane potential changes by JC-1 staining (E).
Fig. 2 (See legend on previous page.)
treatment, cells were exposed to 100 μM of TMZ (Sigma, USA) for 48 h and then collected for further investigation.

Cell transfection
Short hairpin RNA targeting ADM (sh1-ADM or sh2-ADM) was used to achieve the knockdown of ADM (GenePharma, Shanghai, China). miR-1297 expression was intervened through the transfection of miR-1297 mimics/inhibitor (GenePharma). All the transfection was performed using Lipofectamine 3000 reagent (Invitrogen). Cells were seeded in 6/96-well plates. After transfection, cells were subjected to 24/48-h incubation for subsequent analysis.

Cell counting kit-8 (CCK-8) for cell viability
Cell viability was measured using the CCK-8 (Beyotime, China). Cells (1.0 × 10⁴ cells/well) were seeded into 96-well plates. Following an overnight incubation (37°C), cells underwent 4-h incubation (37°C) with 10 μL CCK-8 in 100 μL serum-free DMEM. A microplate reader (Bio-Rad, model 680; Hercules, CA, USA) was utilized to determine the optical density at 490 nm.

qRT-PCR
Total RNA of tissues and cells was extracted by TRIzol (Invitrogen, USA). miRNA and mRNA expressions were determined utilizing the SYBR Green PCR kit (Qiagen, Hilden, Germany). RNU6B (for miRNA) and GAPDH (for mRNA) served as endogenous references. Data were analyzed using the 2⁻ΔΔCT method. The primer sequence was listed in Additional file 1: Table S1.

Immunoblotting
Immunoblotting was used for measuring the protein levels of ADM, pro-caspase-3, pro-caspase-9, cleaved caspase-3/9, Bax, Bcl-2, cleaved PARP, Akt, p-Akt, Erk1/2, and p-Erk1/2. All cells were lysed in 1% PMSF-contained RIPA buffer. After extraction, protein samples were separated by loading onto SDS-PAGE gel, followed by transferring to PVDF membranes. After that, membranes were blocked with 2% bovine serum albumin in TBST, followed by an overnight incubation (4°C) with primary antibodies: ADM (ab69117, Abcam, Cambridge, MA, USA), caspase-3 (19677-1-AP, Proteintech, Wuhan, China), caspase-9 (10380-1-AP, Proteintech), Bax (50599-2-Ig, Proteintech), Bcl-2 (12789-1-AP, Proteintech), cleaved PARP (13371-1-AP, Proteintech), Akt (Y409094, Applied Biological Materials Inc., Richmond, Canada), p-Akt (66444-1-1 g, Proteintech), Erk1/2 (67170-1-Ig, Proteintech), and p-Erk1/2 (sc-81492, Santa Cruz, Dallas, TX, USA). Next, membranes underwent an incubation with HRP-labeled secondary antibody, followed by visualization using ECL Substrates (Millipore, MA, USA). GAPDH served as an internal reference.

Flow cytometry
The apoptosis analysis was performed using the Annexin V-FITC/PI Apoptosis Detection Kit (KeyGEN BioTech, Nanjing, China) following the aforementioned method [28]. The excitation (Ex) and emission (Em) wavelengths are 488 nm and 530 nm, separately. The FITC positive/PI positive and FITC positive/PI negative cells were considered as apoptotic cells. The negative control was shown in Additional file 2: Fig. S1. The mitochondrial membrane potential (ΔΨm) change was also determined by flow cytometry. Briefly, cells were collected and incubated with 10 µg/mL JC-1 staining solution (Yeasen, Shanghai, China) for 15 min at a cell culture incubator. Then, cells were analyzed by flow cytometry immediately (Ex = 488 nm, Em = 530 nm). The rate of Q2 quadrant represented no loss of ΔΨm.

Dual-luciferase reporter assay
After ADM 3'-UTR amplification by PCR, wt-ADM 3'-UTR was constructed by cloning ADM 3'-UTR into the psiCHECK-2 vector (Promega, Madison, WI, USA) downstream of the Renilla gene. mut-ADM 3'-UTR was constructed by mutating ADM seed region for the removal of all complementarity to miR-1297. The above vectors were co-transfected with miR-1297 mimics/inhibitor into 293T cells. After transfection for 48 h, luciferase assays were carried out applying the Dual-Luciferase Reporter Assay System (Promega). The Renilla luciferase activities were normalized to firefly luciferase activities.

Nude mice tumorigenecity assay
All animal protocols were performed under the approval of the Animal Care and Used Committee of Sichuan Provincial People's Hospital. LN-229 cells were randomly divided into 4 groups and transfected with ADM stable knockdown vector (lentivirus mediated shRNA-ADM)
Fig. 3 (See legend on previous page.)
miR-1297 is an upstream regulatory miRNA for ADM. A: TargetScan, miRDB, miRanda, mirDIP, and Starbase were used to predict miRNAs that might target ADM; cross-checked results were compared with miRNAs downregulated in tumor samples. B: The expression levels of four candidates were examined in normal non-cancerous samples (n=18), stage I+II glioma samples (n=8), and stage III+IV glioma samples (n=10) using qRT-PCR. C: The expression levels of four candidates were examined in a normal human glial cell line SVG p12 and a glioma cell line LN-229 using qRT-PCR. D: miR-1297 overexpression or inhibition was achieved in LN-229 cells by transfecting miR-1297 mimics or inhibitor; miR-1297 overexpression or inhibition was confirmed using qRT-PCR. E, F: LN-229 cells were transfected with miR-1297 mimics or inhibitor and examined for ADM expression using qRT-PCR and ADM protein levels by Immunoblotting. G: Wild- and mutant-type ADM luciferase reporters were constructed as described and co-transfected in 293 T cells with miR-1297 mimics or inhibitor; luciferase activity was determined.
and shRNA control vector (lentivirus mediated shRNA-NC) were harvested at logarithmic phase and resuspended into serum-free medium at 1 × 10⁷ per milliliter. Then, 0.2 mL cell suspension were subcutaneously injected into 4 weeks BALB/c nude mice (weighting at 18–20 g, purchased from Laboratory Animal Research Institute of Sichuan Provincial People’s Hospital), at the right side of armpit. When all the groups formed the tumor at approximately one week, mice were injected intraperitoneally with TMZ or DMSO (30 mg/kg/day) every 3 days for another 3 weeks [29]. At end of the experiment, the length (mm), width (mm) and height (mm) of tumor tissues were measured by a vernier caliper, and tumor volume was calculated according to the following formula: Volume = length × width²/2. All implanted mice were sacrificed and the tumor tissues were collected for the subsequent analysis.

**Histological analyses**

Hematoxylin and eosin (H&E) and immunohistochemical (IHC) staining were performed as previously described [30]. Mice tumor samples were fixed in 4% paraformaldehyde in PBS overnight, paraffin-embedded, and cut into 5-μm-thick sections. IHC analysis was performed for the protein level and distribution of Ki-67 using anti-Ki-67 (ab15580; Abcam).

**Statistical analysis**

Experimental data were represented as means ± standard deviation (SD). Differences among groups were identified using one-way analysis of variance (ANOVA), followed by the Tukey’s test. The GraphPad Prism software (ver. 7.0; GraphPad, La Jolla, CA, USA) was utilized for all statistical analyses. *P* < 0.05 was considered as statistically significant.

**Results**

**ADM is specifically upregulated in glioma tissues and TMZ-resistant glioma cell strains**

For verifying ADM expression in TMZ-resistant glioma cells, several datasets downloaded from GEO were analyzed. According to GSE68029, ADM expression was significantly upregulated in glioblastoma stem cells (GSCs) that survived after 500 μM TMZ treatment compared with untreated GSCs (Fig. 1A). According to GSE113510, ADM expression was significantly upregulated in induced LN-229 cell lines with resistance to TMZ than that in regular LN-229 cell lines (Fig. 1B). According to GSE46531, ADM expression was significantly upregulated in TMZ-resistant glioblastoma stem cell clones (Fig. 1C). According to TCGA-GBMLGG, ADM expression was significantly upregulated samples with radiation-therapy compared with that in samples without radiation-therapy (Fig. 1D). In addition, according to GSE4412 and GSE4290, ADM levels were higher in the high-grade glioma tissue samples (Additional file 3: Fig. S2A-B). Moreover, the high expressed ADM was associated with poor overall survival of glioma patients based on CGGA and TCGA-GBMLGG datasets (Additional file 3: Fig. S2C and D). In the clinical collected samples, we also found that ADM mRNA and protein level was higher within advanced-stage samples compared with early-stage samples and adjacent non-cancerous peritumoral edema samples (Additional file 3: Fig. S2E and F). Then, ADM expression was determined within a normal human glial cell line SVG p12 and glioma cell lines (U87-MG, A-172, LN-229, and T98G) using qRT-PCR; ADM expression was dramatically increased within glioma cell lines than that within SVG p12 cell line, in particular in LN-229 cells (Fig. 1E).

**ADM knockdown sensitizes glioma cells to TMZ treatment**

Considering that ADM expression is upregulated in glioma tissues and TMZ-resistant glioma cells, ADM knockdown was achieved in LN-229 cells by transfecting short hairpin RNA targeting ADM (sh1-ADM or sh2-ADM); ADM knockdown was confirmed using qRT-PCR (Fig. 2A). Then, we transfected LN-229 cells with sh-NC or sh-ADM, treated or non-treated with TMZ, and examined for cellular phenotypes. As for cell viability, single sh1-ADM/sh2-ADM transfection or single TMZ treatment significantly suppressed cell viability compared with sh-NC or non-treatment group; ADM knockdown promoted TMZ inhibition upon the viability of glioma cells (Fig. 2B). As for cell apoptosis, single sh1-ADM/sh2-ADM transfection or single TMZ treatment significantly suppressed cell viability compared with sh-NC or non-treatment group; ADM knockdown promoted TMZ inhibition upon the viability of glioma cells (Fig. 2B).
Fig. 5 (See legend on previous page.)
ADM, Bcl-2, p-Akt/Akt, and p-Erk1/2/Erk1/2, along with the elevated cleaved caspase 3/9, Bax and cleaved PARP levels; ADM knockdown enhanced TMZ effects on these factors (Fig. 2D). Moreover, ΔΨm could be diminished by ADM transfection or TMZ treatment, and ADM knockdown further enhanced the suppressive effects of TMZ on ΔΨm (Fig. 2E).

In vivo effects of ADM knockdown on the TMZ treatment of glioma

To further explore the effects of ADM knockdown on the TMZ treatment of glioma cells in vivo, a subcutaneous tumor model in nude mice was established and part of the mouse model received TMZ treatment. Either single ADM knockdown or TMZ treatment significantly decreased tumor sizes, volume and weight; ADM knockdown enhanced the efficacies of TMZ in glioma (Fig. 3A–C). H&E staining was then performed to examine the histopathological characteristics of the tumors; Fig. 3D showed that ADM knockdown or TMZ treatment increased the necrosis of tumor tissues. Then, the level of proliferation marker protein Ki-67 was detected in the tumors by IHC staining. Either single ADM knockdown or TMZ treatment notably decreased Ki-67 protein; ADM knockdown enhanced the effect of TMZ in glioma (Fig. 3E). Single ADM knockdown or single TMZ treatment significantly decreased the protein levels of ADM, Bcl-2, p-Akt/Akt, and p-Erk1/2/Erk1/2, while elevated the cleaved caspase 3/9, Bax and cleaved PARP levels in tumors; and ADM knockdown enhanced TMZ effects on these factors (Fig. 3F).

miR-1297 is an upstream regulatory miRNA for ADM

Considering the crucial role of miRNAs in glioma chemo-resistance [31, 32], next, miRNAs that might target ADM were analyzed. miRNAs that may target ADM were predicted using TargetScan, miRDB, miranda, mirDIP, and Starbase; 8 miRNAs (hsa-miR-367-3p, hsa-miR-26a-5p, hsa-miR-363-3p, hsa-miR-92b-3p, hsa-miR-410-3p, hsa-miR-92a-3p, hsa-miR-32-5p, and hsa-miR-1297) were identified (Fig. 4A). Among these 8 miRNAs, hsa-miR-367-3p [33, 34], hsa-miR-410-3p [35], hsa-miR-32-5p [36, 37], and hsa-miR-1297 [38–41] have been reported down-regulated in gliomas before (Fig. 4A). We examined the expression of these four miRNAs within normal non-cancerous samples (n = 18), and glioma samples (8 stage I + II and 10 stage III + IV) using qRT-PCR; Fig. 4B showed that although four miRNAs were decreased within glioma samples, hsa-miR-1297 was dramatically decreased within advanced-stage samples compared with early-stage samples. Consistently, these four miRNAs were decreased in LN-229 cells relative to those in SVG p12 cells (Fig. 4C). Thus, we chose miR-1297 for subsequent analysis.

miR-1297 mimics/inhibitor was transfected to LN-229 cells for miR-1297 overexpression/inhibition, as confirmed by qRT-PCR (Fig. 4D). In LN-229 cells, miR-1297 overexpression downregulated ADM expression and decreased ADM protein level, while miR-1297 inhibition upregulated ADM expression and increased ADM protein level (Fig. 4E, F). Then, we constructed wild- and mutant-type ADM luciferase reporters, which were then co-transfected with miR-1297 mimics/inhibitor into 293 T cells, followed by the examination of luciferase activity. As shown by Fig. 4G, when cotransfected with wt-ADM and miR-1297 mimics/inhibitor, miR-1297 overexpression suppressed, whereas miR-1297 inhibition enhanced wt-ADM luciferase activity. However, co-transfection of mut-ADM with miR-1297 mimics/inhibitor failed to change the luciferase activity of mut-ADM.

miR-1297 overexpression sensitizes glioma cells to TMZ

Considering that knockdown of ADM sensitizes glioma cells to TMZ and that miR-1297 targets ADM to inhibit ADM expression, we investigated the specific effects of miR-1297 upon TMZ sensitivity of glioma cells. We transfected LN-229 cells with mimics NC/miR-1297 mimics, treated or non-treated these cells with TMZ, and examined for cell phenotypes. Firstly, the level of miR-1297 was determined. miR-1297 levels were effectively increased by miR-1297 mimics and TMZ treatment (Fig. 5A). In contrast, miR-1297 mimics reduced ADM expression and further enhanced the reduction effect of TMZ on ADM expression (Fig. 5C). miR-1297 overexpression alone inhibited the viability of glioma cells and enhanced TMZ inhibition upon the viability of glioma cells (Fig. 5B). Consistently, miR-1297 overexpression alone promoted cell apoptosis and enhanced TMZ promotion upon glioma cell apoptosis (Fig. 5D). miR-1297 overexpression also notably reduced the levels of Bcl-2, p-Akt/Akt, and p-Erk1/2/Erk1/2, together with the increased cleaved caspase 3/9, Bax and cleaved PARP levels; overexpressed miR-1297 enhanced the efficacy of TMZ treatment.

(See figure on next page.)

Fig. 6 ADM knockdown partially attenuated the effects of miR-1297 inhibition on TMZ-treated glioma cells LN-229 cells were co-transfected with sh-ADM and miR-1297 inhibitor, treated with TMZ, and examined for miR-1297 expression by RT-PCR (A); cell viability by CCK-8 assay (B); ADM expression by immunoblotting (C); cell apoptosis by Flow cytometry (D); the protein levels of cleaved caspase 3, pro-caspase 3, cleaved caspase 9, pro-caspase 9, Bax, Bcl-2, p-Akt, Akt, p-Erk1/2, and Erk1/2 by Immunoblotting (E); mitochondrial membrane potential changes by JC-1 staining (F)
Fig. 6 (See legend on previous page.)
TMZ effects on these factors (Fig. 5E). Moreover, ΔΨm was also diminished by miR-1297 overexpression, and miR-1297 overexpression enhanced the suppressive effects of TMZ on ΔΨm (Fig. 5F). Thus, miR-1297 also enhances glioma cell sensitivity to TMZ treatment.

ADM knockdown partially attenuated the effects of miR-1297 inhibition on TMZ-treated glioma cells

Lastly, since miR-1297 targets ADM to inhibit ADM expression, it was investigated that whether miR-1297/ADM axis had a synergistic effect on glioma cell sensitivity to TMZ treatment. We co-transfected LN-229 cells with sh-ADM and miR-1297 and examined for miR-1297 and ADM expression and cell phenotypes. Under TMZ treatment, miR-1297 levels were effectively reduced by miR-1297 inhibitor and were not changed in response to ADM knockdown (Fig. 6A). While, miR-1297 inhibitor increased ADM expression which could be reversed by ADM knockdown (Fig. 3C). ADM knockdown inhibited, whereas miR-1297 inhibition promoted glioma cell viability; ADM knockdown partially attenuated miR-1297 inhibition effects on cell viability (Fig. 6B). Similarly, under TMZ treatment, ADM knockdown promoted, whereas miR-1297 inhibition suppressed glioma cell apoptosis; ADM knockdown partially attenuated miR-1297 inhibition effects on glioma cell apoptosis (Fig. 6C). Consistently, ADM knockdown decreased the protein levels of ADM, Bcl-2, p-Akt/Akt, and p-Erk1/2/Erk1/2, along with elevated cleaved caspase 3/9, Bax and cleaved PARP, while miR-1297 inhibition showed opposite effects; ADM knockdown partially attenuated miR-1297 inhibition effects on these proteins (Fig. 6E). ΔΨm was diminished by ADM knockdown but amplified by miR-1297 inhibition, and ADM knockdown partially attenuated miR-1297 inhibition effects on ΔΨm (Fig. 6F).

Discussion

In the present study, ADM expression has been found upregulated in glioma tissues and TMZ-resistant glioma cells based on bioinformatics and experimental analyses. Knocking down ADM in glioma cells enhanced the suppressive effects of TMZ on glioma cell viability, promoting effects on cell apoptosis, and inhibitory effects on mitochondrial membrane potential. Moreover, ADM knockdown also enhanced TMZ effects on Bax/Bcl-2, Akt phosphorylation, and Erk1/2 phosphorylation. miR-1297 directly targeted ADM and inhibited ADM expression. miR-1297 overexpression exerted similar effects to ADM knockdown on TMZ-treated glioma cells. More importantly, under TMZ treatment, inhibition of miR-1297 attenuated TMZ effects on glioma cells; ADM knockdown partially attenuated the effects of miR-1297 inhibition on TMZ-treated glioma cells.

ADM, a member of the calcitonin-family of peptides, has approximately 24% homology with calcitonin-gene-related peptide (CGRP) [42]. Peptides of the CGRP family are extensively found in the body and exert crucial biological effects, such as mediating calcium regulation [43], glucose metabolism [44], and cardiovascular functions [45]. ADM has been reported as one of 5 candidate genes associated with glioma resistance to TMZ, which showed to be consistently linked to higher expression of DDIT4 and lower prognosis in TMZ-treated cells [46]. Adrenomedullin 2, another CGRP member, increased glioma cell invasion and proliferation via enhancing the formation of filopodia, which depends on the activation of Erk1/2 pathway [47]. In this study, ADM expression has been found upregulated in TMZ-resistant glioma samples, suggesting the underlying effect of ADM on glioma cell TMZ resistance. As expected, ADM knockdown in glioma cells amplified the suppression of TMZ on glioma cell viability and promotive effects on cell apoptosis. Moreover, ADM knockdown also enhanced TMZ effects on Bax/Bcl-2, Akt phosphorylation, and Erk1/2 phosphorylation. These data suggest that ADM knockdown might sensitize glioma cells to TMZ treatment, and the Bax/Bcl-2, Akt, and Erk1/2 signaling might be involved. Notably, ADM knockdown also enhanced the inhibitory effects of TMZ on mitochondrial membrane potential. Reportedly, ADM upregulated the mRNA expression and peptide level of oncogene Bcl-2 within Ishikawa cells under the condition of normoxia and anoxia. It has shown that Bcl-2 has protective effects in response to many different apoptotic stimuli, such as hypoxia [48]. Bcl-2 prevents apoptosis, which may be achieved by blocking the release of Cytochrome c from mitochondria, and then inhibiting caspase-3 activation and the subsequent apoptotic effects [49]. Herein, ADM knockdown or TMZ treatment induced caspase 3 and caspase 9 cleavage, as well as mitochondrial membrane potential impairment, suggesting that mitochondrial function might also be involved in ADM knockdown enhancing glioma cell sensitivity to TMZ treatment.

As promising agents that could inhibit the expression of downstream target mRNAs, miRNAs play a critical role in carcinogenesis through regulating different targets’ expressions. Various studies have indicated that miRNAs can be efficient biomarkers of glioma and used as therapeutic targets/agents [50–52]. In this study, miR-1297 has been predicted as an upstream regulatory miRNA for ADM. Through direct targeting, miR-1297 inhibited ADM expression. It has been validated that miR-1297 exerts antitumor effects on glioma. Through regulating HMGA1, miR-1297 inhibited glioma cell growth in vivo and in vitro [39]. Another group demonstrated that miR-1297 inhibited in vitro glioma cell invasion, migration
and proliferation through targeting EZH2 [38]. In this study, single miR-1297 overexpression enhanced TMZ effects on glioma cells, whereas miR-1297 inhibition attenuated TMZ effects; more importantly, ADM knockdown significantly attenuated miR-1297 inhibition effects on TMZ-treated glioma cells. These data indicate that miR-1297/ADM axis affects glioma cell sensitivity to TMZ treatment.

In conclusion, miR-1297 sensitizes glioma cells to TMZ treatment through targeting ADM. The Bax/Bcl-2, Akt, and Erk1/2 signaling pathways, as well as mitochondrial functions might be involved.

### Supplementary Information

The online version contains supplementary material available at [https://doi.org/10.1186/s12967-022-03647-6](https://doi.org/10.1186/s12967-022-03647-6).

### Authors contributions

ZH, MC, JH made substantial contribution to the conception and design of the work; LL, PL analyzed and interpreted the data; ZH, JT collected grants; Final approval of the work: all authors.

### Funding

This study was supported by the Foundation for Sichuan Provincial People’s Hospital (No. 2021LY03) and Medico-Engineering Cooperation Funds from University of Electronic Science and Technology of China (No. ZYGX2021YQLH209).

### Availability of data and materials

Please contact the authors for data requests.

### Declarations

**Ethics approval and consent to participate**

Not Applicable.

**Consent for publication**

Not Applicable.

**Competing interests**

The authors confirm that there are no conflicts of interest.

### Author details

1. Department of Neurosurgery, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, No.32 West Second Section First Ring Road, Chengdu 610072, Sichuan, China. 2. Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu 610072, China.

---

Received: 27 March 2022   Accepted: 18 September 2022
Published online: 01 October 2022

### References

1. Weller M, Wick W, Alapeke K, Brada M, Berger M, Pfister SM, Nishikawa R, Rosenthal M, Wen PY, Stupp R, Reifenberger G. Glioma. Nat Rev Dis Primers. 2015;1:15017.

2. Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, Weller M. Advances in the molecular genetics of gliomas—implications for classification and therapy. Nat Rev Clin Oncol. 2017;14:434–52.

3. Wick W, Platten M, Meisner C, Feltsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinaehn JP, Sabel M, Combs SE, Vesper J, Braun C, Mesenssenger J, Ketterm R, Mayer-Steinacker R, Reifenberger G, Weller M. Society.NOASGoN-oWG0Gc: temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012;13:707–15.

4. Sandmann T, Bourgon R, Garcia J, Li C, Clough Esy, Tchiout OLI, Wick W, Nishikawa R, Mason W, Henriksson S, San F, Lai A, Moore N, Kharbana S, Peale F, Hegde P, Abrey LE, Phillips HS, Bas C. Patients with proerineal glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AIAngio trial. J Clin Oncol. 2013;31:2373–44.

5. Miller MJ, Martinez A, Unsworth EJ, Thiele CJ, Moody TW, Elsasser T, Cutitta F. Adrenomedullin expression in human tumor cell lines. Its potential role as an autocrine growth factor. J Biol Chem. 1996;271:23345–51.

6. Ouafik L, Sauze S, Boudouresseque F, Chiot O, Delfino C, Fina F, Vouqueaux V, Durers C, Palami J, Delfour H, Grisoli F, Casellas P, Brunner N, Martin PM. Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. Am J Pathol. 2002;160:1279–92.

7. Fujita Y, Mimata H, Nasu N, Nomura T, Nomura Y, Nakagawa M. Involvement of adrenomedullin induced by hypoxia in angiogenesis in human renal cell carcinoma. Int J Urol. 2002;9:285–95.

8. Oehler MK, Hague S, Rees MC, Bicknell R. Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis. Oncogene. 2002;21:2815–21.

9. Nishimatsu H, Suzaki E, Nagata D, Moriqama N, Sato K, Walsh K, Sata M, Kangawa K, Matsuo H, Santo T, Kitamura T, Hiros Y. Adrenomedullin induces endothelium-dependent vasorelaxation via the phosphatidylinositol 3-kinase/Akt-dependent pathway in rat aorta. Circ Res. 2001;89:63–70.

10. Okamura H, Naga Y, Itoh T, Okano I, Hino J, Mori K, Tsukamoto Y, Ishibashi-Ueda H, Miwa S, Tambara K, Toyokuni S, Yutani C, Kangawa K. Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation. 2004;109:242–8.

11. Fritz-Six KL, Durworth WP, Li M, Caron KM. Adrenomedullin signaling is necessary for murine lymphatic vascular development. J Clin Invest. 2008;118:40–50.

12. Oehler MK, Norbury C, Hague S, Rees MC, Bicknell R. Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth. Oncogene. 2001;20:2937–45.

13. Lo Dico A, Valtorta S, Ottobrin I, Moresco RM. Role of metformin and AKT phosphorylation on TMZ-treated glioma cells. Front Oncol. 2019;9:463.

14. Sato A, Sunayama J, Matsuda K, Seino S, Suzuki K. Adrenomedullin promotes angiogenesis in human renal cell carcinoma. Int J Urol. 2002;9:285–95.

15. Huang T, Alvarez A, Hu B, Cheng SY. Noncoding RNAs in cancer and cancer stem cells. Chin J Cancer. 2013;32:582–93.

16. Huang T, Alvarez AA, Pangeni RP, Horbinski CM, Lu S, Kim SH, James CD, J Razer J, J Kessler J, Brienann CW, Sulman EP, Finocchia G, Tan M, Nishikawa R, Lu X, Nakano I, Hu B, Cheng SY. A regulatory circuit of miR-125b/miR-20b and Wnt signaling controls glioblastoma phenotypes through Fzd6-modulated pathways. Nat Commun. 2016;7:12885.
17. Ling H, Zhang W, Calin GA. Principles of microRNA involvement in human cancers. Chin J Cancer. 2011;30:739–48.

18. Liu B, Bao YK, Yang JM, Cheng Y. Targeting autophagic pathways for cancer drug discovery. Chin J Cancer. 2013;32:115–20.

19. Casco S, D’Andrea A, Ferla R, Surmacz E, Gulotta E, Amodeo V, Bazan V, Gebbia N, Russo A. miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol. 2010;224:224–9.

20. Li D, Ilnitsky S, Kovalchuk A, Khachigian LM, Bronson RT, Wang B, Kovalchuk O. Crucial role for early growth response-1 in the transcriptional regulation of miR-20b in breast cancer. Oncotarget. 2013;4:1373–87.

21. So AV, Zhao JL, Baltimore D. The Yin and Yang of microRNAs: leukemia and immunity. Immuno Rev. 2013;253:129–45.

22. Li S, Li W, Chen G, Huang J, Li W. MiRNA-27a-3p induces temozolomide resistance in glioma by inhibiting NF1 level. Am J Transl Res. 2020;12:4749–56.

23. Huang T, Wan X, Alvarez AA, James CD, Song X, Yang Y, Sastry N, Nakanoo I, Sulman EP, Hu B, Cheng SY. MiR-993 (microRNA-993) regulates tumorigenicity and therapy response of glioblastoma by targeting autophagy. Autophagy. 2019;15:1100–11.

24. Huang W, Zhong Z, Luo C, Xiao Y, Li L, Zhang X, Yang L, Xiao K, Ning Y, Chen L, Liu Q, Hu X, Zhang J, Ding X, Xiang S. The miR-26a/PA-2alpha/Panog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma. TheraREV. 2019;19:5497–516.

25. Yin J, Zeng A, Zhang Z, Shi Z, Yan W, You Y. Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma. EBioMedicine. 2019;42:238–51.

26. Lu C, Wei Y, Wang X, Zhang Z, Yin J, Li W, Chen L, Lyu X, Shi Z, Yan W, You Y. DNA-methylation-mediated activating of IncRNA SNHG12 promotes temozolomide resistance in glioblastoma. Mol Cancer. 2020;19:28.

27. Li H, Chen L, Li J, Zhou Q, Huang A, Liu WW, Wang K, Gao L, Qi ST, Lu YT. MiR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3/Bcl2 signaling pathway. J Hematol Oncol. 2018;11:70.

28. Jin X, Cai L, Wang C, Deng X, Yi S, Lei Z, Xiao Q, Xu H, Luo H, Sun J. CASCA2/miR-24/miR-221 modulates the TRAIL resistance of hepatocellular carcinoma cell through caspase-8/caspase-3. Cell Death Dis. 2018;9:918.

29. Sun J, Ma Q, Li B, Wang C, Mo L, Zhang X, Tang F, Wang Q, Yan X, Yao X, Wu Q, Shu C, Xiong J, Fan W, Wang J. RPN2 is targeted by miR-181c and mediates glioma progression and temozolomide sensitivity via the wnt/beta-catenin signaling pathway. Cell Death Dis. 2020;11:890.

30. Guo Z, Zhang W, Xia G, Niu L, Zhang Y, Wang Y, Jiang B, Wang J. Sph1 upregulates the four and half lim 2 (FHL2) expression in gastrointestinal cancers through transcription regulation. Mol Carcinog. 2010;49:826–36.

31. Kosgodage US, Uysal-Onganer P, MacLatchy A, Kraev I, Chatterton NP, Nicholas AP, Inal JM, Lange S. Peptidylarginine deiminases post-translational deiminate prohibitin and modulate extracellular vesicle release and micromas in glioblastoma multiforme. Int J Mol Sci. 2018;20:103.

32. Cen L, Liu R, Liu W, Li Q, Cui H. Competing endogenous RNA networks in glioma. Front Genet. 2021;12:675498.

33. Liu X, Zheng J, Xue Y, Yu H, Gong W, Wang P, Li Z, Yu Y. PIWIL3/OIP5-AS1/miR-367-3p/CEBPA feedback loop regulates the biological behavior of glioma cells. Theranostics. 2018;8:1084–105.

34. Guan Y, Chen L, Bao Y, Qiu B, Pang C, Cui R, Wang Y. High miR-196a and low miR-367 cooperatively correlate with unfavorable prognosis of high-grade glioma. Int J Clin Exp Pathol. 2015;8:6576–88.

35. Wang C, Huang S, Rao S, Hu J, Zhang Y, Luo J, Wang H. Decreased expression of miR-410-3p correlates with poor prognosis and tumorigenesis in human glioma. Cancer Manag Res. 2019;11:10581–92.

36. Zhang Y, Wang J, An W, Chen C, Wang W, Zhu C, Chen F, Chen H, Zheng W, Gong J. MiR-32 inhibits proliferation and metastasis by targeting EZH2 in glioma. Technol Cancer Res Treat. 2019;18:1530338319854132.

37. Wu J, Li R, Li L, Gu Y, Zhan H, Zhou C, Zhong C. MYC-activated IncRNA HNF1A-AS1 overexpression facilitates glioma progression via cooperating with miR-32-3p/SOX4 axis. Cancer Med. 2020;9:6387–98.

38. Liu L, Li X, Shi Y, Chen H. Long noncoding RNA DLGAP1-AS1 promotes the progression of glioma by regulating the miR-1297/EZH2 axis. Aging (Albany NY). 2021;13:12129–42.

39. Wang J, Xu X, Mo S, Tian Y, Wu J, Zhang J, Zhao J. Involvement of microRNA-1297, a new regulator of HMG1A, in the regulation of glioma cell growth in vivo and in vitro. Am J Transl Res. 2016;8:2149–58.

40. Song D, Ye L, Xu Z, Jin Y, Zhang L. CircRNA hsa_circ_0030018 regulates the development of glioma via regulating the miR-1297/RAB21 axis. Neoplasma. 2021;68:391–403.

41. Li H, Yuan H. MiR-1297 negatively regulates metabolic reprogramming in glioblastoma via repressing KPN2A2. Hum Cell. 2020;33:619–29.

42. Wimalawansa SJ, Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Crit Rev Neurobiol. 1997;11:167–239.

43. Naot D, Cornish J. The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism. Bone. 2008;43:813–8.

44. Ruzicka E, Toth M, Tullassy Z, Somogyi A. Adrenomedullin and diabetes mellitus. Diabetes Metab Rev. 2001;17:321–9.

45. Hong Y, Hay DL, Quirion R, Poyner DR. The pharmacology of adrenomedullin 2/intermedin. Br J Pharmacol. 2012;166:110–20.

46. Ho KH, Chen PH, Chou CM, Shih CM, Lee YT, Cheng CH, Chen KC. A key role of DNA damage-inducible transcript 4 (DDIT4) connects autophagy and GLUT5-mediated stemness to desensitize temozolomide efficacy in glioblastomas. Neurotherapeutics. 2020;17:1212–27.

47. Huang L, Wang D, Feng Z, Zhao H, Xiao F, Wei Y, Zhang H, Li H, Kong L, Li M, Liu F, Zhang H, Wang W. Inhibition of intermedin (Adrenomedullin 2) suppresses the growth of glioblastoma and increases the antitumor activity of temozolomide. Mol Cancer Ther. 2021;20:284–95.

48. Shimizu S, Eguchi Y, Kameki W, Itoh Y, Hasegawa J, Yamabe K, Otsuki Y, Matsuda H, Tsujimoto Y. Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-XL. Cancer Res. 1996;56:2161–6.

49. Yang J, Liu X, Bhalla K, Kim CN, Inbrad AM, Cai J, Peng TJ, Jones DP, Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997;275:1129–32.

50. Mondal I, Kulshreshtha R. Potential of microRNA based diagnostics and therapeutics in glioma: a patent review. Expert Opin Ther Pat. 2021;31:91–106.

51. Sun J, Li B, Shu C, Ma Q, Wang J. Functions and clinical significance of circular RNAs in glioma. Mol Cancer. 2020;20:19:34.

52. Saadatpour L, Fadaee E, Fadaei S, Nassiri Mansour R, Mohammad M, Mousavi SM, Goodarzi M, Verdi J, Mirzaei H. Glioblastoma: exosome and microRNA as novel diagnosis biomarkers. Cancer Gene Ther. 2016;23:415–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.